Summary by Moomoo AI
On November 14, 2024, iBio Inc, a biotechnology company, was the subject of a Schedule 13G/A filing with the United States Securities and Exchange Commission. The filing indicated that ADAR1 Capital Management, LLC, along with ADAR1 Capital Management GP, LLC, and Daniel Schneeberger, collectively reported shared voting and dispositive power over 966,298 shares of iBio Inc's common stock, representing 9.99% of the company's class. The shares include common stock and shares underlying pre-funded and milestone warrants held by ADAR1 Partners, LP, with certain ownership limitations in place. The filing was made in accordance with Rule 13d-1(b) of the Securities Exchange Act of 1934, indicating that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of iBio Inc. The principal business office for the reporting persons is located in Austin, Texas, and the filing was jointly signed by Daniel Schneeberger, who may be deemed to indirectly beneficially own the securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC.
